biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by cornpieon Aug 06, 2017 12:02pm

84 Views

Post# 26552138

RE:RE:Non-Human Primates

BTI may very well bring a drug to Market--and it could be a 100x's today's price--, but really, statistically, their probability of doing so is less than 10% and years away...............rusty cat if you believe that then what percentage do you give to any one or more of BTI's partners or collaboration bringing a drug to market using the Transcend licensing model?

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario